three years of regulatory threads, summarised so you do not have to read them
The title is the argument: three years of regulatory threads, summarised so you do not have to read them. Here is the rest of it. Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim. Research-use-only material is not…
The evidence base, described honestly, which almost no summary of it does.
The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.
That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.
The evidence base, described honestly, which almost no summary of it does.
dose_diary_dana is right that a pure something-else is still something else.
preclinical enthusiasm is not clinical evidence
identity, quantity, stability — three separate questions
a fifteen-residue peptide is easy to make and easy to make badly
That claim traces back to a single preclinical paper that says something considerably narrower.